Explore

TrendlineTrendline
ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth

ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth

ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth
TrendlineTrendline
Alvotech Reports Decreased Total Revenue for Nine Months Ending September 2026, Maintains Full-Year Guidance

Alvotech Reports Decreased Total Revenue for Nine Months Ending September 2026, Maintains Full-Year Guidance

Alvotech Reports Decreased Total Revenue for Nine Months Ending September 2026, Maintains Full-Year Guidance
TrendlineTrendline
Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials
Rapid ReadRapid Read
FDA Clears Metagenomi's IND for MGX-001, a One-Time Genome Editing Therapy for Hemophilia A

FDA Clears Metagenomi's IND for MGX-001, a One-Time Genome Editing Therapy for Hemophilia A

The FDA has cleared Metagenomi Therapeutics' Investigational New Drug (IND) application for MGX-001, its lead genome editing program for hemophilia A. This clearance allows the company to initiate a first-in-human Phase 1/2 trial for the one-time therapy in adults and children with moderately severe to severe hemophilia A. MGX-001 is designed to site-specifically integrate the Factor VIII (FVIII) gene into a 'safe harbor' location within the albumin gene, utilizing the body's native albumin promoter to drive durable, endogenous FVIII production. The therapy uses an adeno-associated virus (AAV) vector for the FVIII gene cassette and a lipid nanoparticle (LNP) to deliver mRNA encoding a proprietary Type V CRISPR nuclease.
TrendlineTrendline
Medical Device and Equipment Certification Market Driven by Regulatory Frameworks and Patient Safety

Medical Device and Equipment Certification Market Driven by Regulatory Frameworks and Patient Safety

Medical Device and Equipment Certification Market Driven by Regulatory Frameworks and Patient Safety
TrendlineTrendline
Mirum Pharmaceuticals Achieves Primary Endpoint in AZURE-4 Phase 3 Study for Chronic Hepatitis Delta Virus Treatment

Mirum Pharmaceuticals Achieves Primary Endpoint in AZURE-4 Phase 3 Study for Chronic Hepatitis Delta Virus Treatment

Mirum Pharmaceuticals Achieves Primary Endpoint in AZURE-4 Phase 3 Study for Chronic Hepatitis Delta Virus Treatment
TrendlineTrendline
Swiss Water Decaffeinated Coffee Inc. Reports Record Earnings and Plans Capacity Expansion Amidst Growing Demand

Swiss Water Decaffeinated Coffee Inc. Reports Record Earnings and Plans Capacity Expansion Amidst Growing Demand

Swiss Water Decaffeinated Coffee Inc. Reports Record Earnings and Plans Capacity Expansion Amidst Growing Demand
Rapid ReadRapid Read
IASO Bio's In Vivo CAR-T Therapy Receives Simultaneous FDA and NMPA IND Approvals

IASO Bio's In Vivo CAR-T Therapy Receives Simultaneous FDA and NMPA IND Approvals

IASO Bio's IASO208, an in vivo CAR-T therapy targeting CD20, has achieved simultaneous Investigational New Drug (IND) clearances from both the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA). The FDA implicitly cleared the IND in September 2026, followed by the NMPA's approval this month through China's 30-day expedited review pathway. This dual clearance allows IASO Bio to leverage its existing clinical data from China to initiate Phase Ib studies in the United States, with plans for larger trials across both regions. The in vivo CAR-T approach, where the gene-editing vector reprograms T cells inside the patient's body, represents a significant advancement compared to current ex vivo CAR-T therapies that require external cell engineering. Early data from an ongoing investigator-initiated trial (IIT) in China involving eleven patients showed favorable tolerability and promising anti-tumor activity, which was presented at the 2026 ASH Annual Meeting.
Rapid ReadRapid Read
FDA Expands Approval for Inhaled Insulin Afrezza for Pediatric Type 1 Diabetes Patients

FDA Expands Approval for Inhaled Insulin Afrezza for Pediatric Type 1 Diabetes Patients

The FDA has expanded its approval for Afrezza, an inhaled insulin, for use in children aged six years and older with diabetes, including type 1 diabetes. This medication offers an alternative to injected mealtime insulin, delivering a dry powder through the lungs into the bloodstream for rapid absorption. The INHALE-1 clinical trial, which evaluated Technosphere insulin (Afrezza) against injected rapid-acting insulin analogs in 230 children and adolescents aged 4 to 17 years, showed mixed results regarding glucose control. While the primary analysis did not establish noninferiority for HbA1c outcomes, a sensitivity analysis did meet this standard. Participants using inhaled insulin reported significantly greater treatment satisfaction and experienced less weight gain. However, Afrezza carries an FDA boxed warning regarding acute bronchospasm in patients with chronic lung disease, making it unsuitable for children with asthma or other chronic lung conditions. Lung function must be evaluated before treatment...
Rapid ReadRapid Read
CRISPR Therapeutics Reports Positive Phase 1b Results for CTX310 in Severe Hypertriglyceridemia

CRISPR Therapeutics Reports Positive Phase 1b Results for CTX310 in Severe Hypertriglyceridemia

CRISPR Therapeutics has announced positive Phase 1b clinical trial results for its investigational gene-editing therapy, CTX310, designed to treat severe hypertriglyceridemia (sHTG). The data, presented at the American Heart Association (AHA) Scientific Sessions 2026, showed a mean 63% reduction in triglycerides (TG) and a 65% reduction in circulating angiopoietin-like protein 3 (ANGPTL3) at Day 30 following a single-course treatment. Participants in the trial had a median baseline triglyceride concentration exceeding 1,000 mg/dL, indicating significant lipid abnormalities. All ten patients in the Phase 1b cohort had diabetes, 30% had a history of pancreatitis, and 20% had existing atherosclerotic cardiovascular disease, and all had failed prior triglyceride-lowering therapies. The therapy works by permanently disabling the ANGPTL3 gene in liver cells using CRISPR-Cas9 technology, which prevents the production of functional ANGPTL3 protein. This allows lipoprotein lipase (LPL), an enzyme that breaks down t...
TrendlineTrendline
Divi's Laboratories Reports 64% Profit Surge in Q2 FY27, Driven by Strong Revenue Growth

Divi's Laboratories Reports 64% Profit Surge in Q2 FY27, Driven by Strong Revenue Growth

Divi's Laboratories Reports 64% Profit Surge in Q2 FY27, Driven by Strong Revenue Growth
TrendlineTrendline
Live Nation Reports Record Q3 2026 Earnings Amidst Ongoing Legal Challenges

Live Nation Reports Record Q3 2026 Earnings Amidst Ongoing Legal Challenges

Live Nation Reports Record Q3 2026 Earnings Amidst Ongoing Legal Challenges